CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

December 15, 2024

Study Completion Date

April 15, 2025

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)

"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2,Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."

Trial Locations (1)

300060

Tianjin Medical University Cancer Insititute & Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER